Benzenesulfonamide

Benzenesulfonamide

SCHEMBL4496281

COc1ccc2cc(C(N)=O)c(Nc3cccc(Cl)c3)nc2c1.NS(=O)(=O)c1ccccc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47
PDE4B Q07343 1/20 0.45
FADS1 O60427 1/20 0.45
SYK P43405 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
BRD4 O60885 1/20 0.43
CSF1R P07333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methanesulfonamide SCHEMBL4500516 0.92 MEN1 (0.49) MEN1KMT2ALMNAHPGDGFER
SCHEMBL5203048 0.91 MEN1 (0.54) MEN1KMT2ALMNAHPGDGFER
SCHEMBL4494028 0.85 MAPT (0.41) MEN1KMT2ALMNAHPGDGFER
SCHEMBL5207437 0.84 MEN1 (0.64) MEN1KMT2ALMNAHPGDGFER
SCHEMBL5208537 0.80 LMNA (0.48) MEN1KMT2ALMNAHPGDGFER
SCHEMBL13973636 0.76 MAPK10 (0.51) SMN1; SMN2KDM4EMAPTCSF1R
SCHEMBL5205074 0.76 MEN1 (0.64) MEN1KMT2ALMNAHPGDGFER
SCHEMBL4482947 0.75 AKR1C3 (0.58) MEN1KMT2ALMNAHPGDSMN1; SMN2
SCHEMBL4496284 0.74 KDM4E (0.53) MEN1KMT2ALMNAHPGDGFER
SCHEMBL5203205 0.73 FADS1 (0.53) MEN1KMT2ALMNAHPGDGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 MEN1 2541/4885KMT2A 3192/4885LMNA 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.